What is melanotan II and why does its structure matter for analysis?
Melanotan II is a superpotent cyclic melanotropic peptide first characterised in the pharmaceutical literature as a rationally designed analogue of alpha-MSH (Dorr et al., 1996). Structurally, it is a seven-residue peptide closed through a lactam bridge between a lysine side chain and an aspartic acid side chain, giving a conformationally constrained ring. This cyclisation is the single most important feature for the analyst, because it alters chromatographic retention, ionisation behaviour and degradation chemistry relative to a linear peptide of similar mass. The monoisotopic and average molecular masses derived from the amino-acid sequence provide the primary identity target for mass spectrometry, while the cyclic constraint tends to produce sharp, reproducible reversed-phase peaks that support precise purity integration. Related melanotropin analogues built on the MT-II scaffold have been reported to demonstrate the sensitivity of activity and physicochemistry to small sequence and ring modifications (Gao et al., 2015), which underscores why sequence-level confirmation, not merely a matching intact mass, is required to distinguish MT-II from closely related structures such as bremelanotide. From a documentation standpoint, characterisation begins by stating the intended sequence, the theoretical molecular formula and the expected exact mass, then generating experimental data to confirm each. Because the peptide is typically supplied as a lyophilised acetate or trifluoroacetate salt, the reported identity must also account for counterion and residual solvent contributions to mass balance — factors addressed separately in net peptide content determination.
How is melanotan II identity confirmed by mass spectrometry?
Identity confirmation for melanotan II relies on mass spectrometry, ideally high-resolution instrumentation. A published forensic study used liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS) to characterise melanotan II and bremelanotide sourced from unregulated markets, demonstrating the technique's ability to resolve and identify these melanocortin peptides with sub-ppm mass accuracy (Mestria et al., 2021). In practice, an electrospray ionisation (ESI) spectrum of MT-II shows the singly and doubly protonated molecular ions; the measured accurate mass is compared against the theoretical value calculated from the molecular formula, with acceptance criteria typically expressed in parts-per-million for HRMS or within a fraction of a mass unit for nominal-resolution instruments. Because a matching intact mass alone cannot exclude isobaric or regiochemical variants, tandem mass spectrometry (MS/MS) is used to generate a fragment-ion ladder that maps back to the expected sequence. For a cyclic peptide, ring-opening fragmentation produces a characteristic series that must be interpreted with the lactam bridge in mind, since fragmentation does not proceed identically to a linear backbone. The COA should record the instrument type, ionisation mode, the observed versus theoretical m/z values, and the charge states detected. Where sequence confirmation is offered, the fragment assignments should be tabulated. Documenting these parameters allows a researcher to independently verify that the material's mass and, where available, its fragmentation pattern are consistent with the declared melanotan II structure rather than a mislabelled or substituted analogue.
How is chromatographic purity of melanotan II assessed?
Chromatographic purity of melanotan II is assessed by reversed-phase high-performance liquid chromatography (RP-HPLC), usually on a C18 stationary phase with a water/acetonitrile gradient modified by an acidic ion-pairing agent such as trifluoroacetic acid. Purity is reported as the percentage area of the main peak relative to total integrated peak area at a defined UV wavelength, commonly 210–220 nm where the peptide bond absorbs strongly. Typical research-grade acceptance criteria set a minimum main-peak area percentage, with individual and total related-substance limits specified separately. The method must be shown to be adequate for its purpose, meaning the main peak is well resolved from adjacent impurities and the baseline is stable across the integration window. A key concept researchers ask about is peak purity: a single symmetrical peak can still conceal a co-eluting impurity, so photodiode-array (PDA) peak-purity analysis or an orthogonal LC-MS check is used to confirm spectral homogeneity across the peak. For MT-II specifically, the cyclic structure generally gives good peak shape, but process-related impurities such as linear precursor, deletion sequences and oxidation products may elute close to the main peak and require a shallow gradient to resolve. The COA should state the column chemistry, mobile-phase composition, gradient, detection wavelength, run time, retention time of the main peak and the resulting purity value. Recording these method details enables reproduction of the assay and meaningful comparison between batches and between suppliers.
What stability and degradation pathways are characterised for melanotan II?
Stability characterisation defines how melanotan II changes over time and under stress, and it is essential for assigning storage conditions and re-test intervals. Early preformulation work on melanotan II examined its solution behaviour and degradation as part of pharmaceutical development (Lan et al., 1994), establishing the peptide as a subject for formal stability study. A stability-indicating HPLC method is one validated to separate the intact peptide from its degradation products, so that any loss of main-peak area is matched by a corresponding rise in related substances. Forced-degradation (stress) studies deliberately expose the peptide to elevated temperature, acidic and basic conditions, oxidative agents such as hydrogen peroxide, and photolytic light to identify the likely degradation chemistry and confirm the method can detect it. For peptides generally, the principal pathways are hydrolysis of labile bonds, oxidation of susceptible residues, aggregation and, for salt forms, counterion or moisture effects; MT-II's lactam ring adds the possibility of ring-related rearrangement. Water content by Karl Fischer titration and appearance of the lyophilised solid are recorded because residual moisture accelerates hydrolytic degradation. The stability documentation for a batch should identify the storage temperature under which the peptide is held and shipped, note that lyophilised material is generally more stable than reconstituted solution, and reference the forced-degradation data that support the stability-indicating claim of the purity method. This framing is analytical only and makes no representation about biological performance.
How is net peptide content and salt correction determined?
The mass of powder in a vial is not the same as the mass of peptide it contains, and net peptide content quantifies the difference. Synthetic peptides are typically isolated as salts — commonly acetate or trifluoroacetate — and retain bound water and residual counterion, all of which add to the gross weight without being peptide. Net peptide content is expressed as the percentage of the gross mass attributable to the peptide backbone itself, and it is usually established by quantitative amino-acid analysis (AAA) or by a validated UV or HPLC assay calibrated against a reference standard. Complementary tests support the calculation: Karl Fischer titration measures water content, and ion chromatography or a dedicated counterion assay quantifies TFA or acetate. Where TFA is the ion-pairing agent used in purification, residual trifluoroacetate is both a mass contributor and a potential analytical interference, so its determination and, where relevant, counterion exchange are documented. Reporting net peptide content lets a researcher calculate the true quantity of peptide present and compare batches on a like-for-like basis rather than by gross vial weight, which can differ substantially at identical labelled amounts. A complete COA therefore separates chromatographic purity (the proportion of peptide-related material that is the target sequence) from net peptide content (the proportion of the total solid that is peptide). Confusing the two is a common misreading; a batch can be 99% pure by HPLC yet contain considerably less than 99% peptide by mass once salt and water are subtracted.
How should a melanotan II certificate of analysis be read and documented?
A certificate of analysis is the consolidated record of a batch's characterisation, and reading it critically is a core research-lab skill. Published analyses of melanotan II obtained from unregulated markets have documented substantial variability and mislabelling in such samples (Mestria et al., 2021), and reports of harm associated with unregulated melanotan II use reinforce that undocumented material carries analytical uncertainty (Reactions Weekly, 2012). A robust COA for MT-II should identify the product name and declared sequence, a unique batch or lot number, the manufacture and re-test dates, and the specific methods used for each attribute. Expect an identity section reporting the observed versus theoretical mass from ESI or HRMS, a purity section giving the RP-HPLC main-peak area percentage with the method conditions, a related-substances summary, net peptide content with the supporting water and counterion data, and appearance. Ideally the actual chromatogram and mass spectrum are appended so the researcher can verify integration and mass assignment rather than trusting a summary figure alone. Traceability links the COA to the sampled batch through the lot number, and lot-release testing against predefined acceptance criteria demonstrates the batch met specification before dispatch. When comparing suppliers, prioritise documents that disclose method detail and raw data over those that state only a headline purity number. This documentation discipline is what separates a characterised research reference material from an uncharacterised one, and it is purely a matter of analytical evidence, not of any claimed effect.
Order Melanotan 2 with documentation
If this guide helped you evaluate Melanotan 2 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Melanotan 2 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
What analytical methods characterise melanotan II?
Identity is confirmed by mass spectrometry, ideally LC-HRMS with tandem MS for sequence confirmation, matching observed against theoretical mass. Purity is measured by reversed-phase HPLC as main-peak area percentage. Supporting tests include Karl Fischer water content, net peptide content by amino-acid analysis, counterion quantification and forced-degradation stability studies.
Why does melanotan II purity differ from net peptide content?
HPLC purity is the proportion of peptide-related material that is the target sequence, while net peptide content is the proportion of total solid mass that is actually peptide after subtracting bound salt and water. A batch can be 99% pure by HPLC yet contain less peptide by mass once acetate or TFA counterion and residual moisture are accounted for.
How is melanotan II identity distinguished from bremelanotide?
Intact mass alone is insufficient because related melanocortin peptides can be confused. Tandem mass spectrometry generates a fragment-ion ladder mapped to the expected sequence, and LC-HRMS provides high mass accuracy to resolve the two. Published forensic LC-HRMS work characterised both peptides in market samples, illustrating the resolving power required.
What does a stability-indicating HPLC method mean for melanotan II?
It is a chromatographic method validated to separate intact melanotan II from its degradation products, so any decline in main-peak area corresponds to detectable related substances. Forced-degradation studies under heat, acid, base, oxidation and light confirm the method can detect the relevant pathways, supporting assigned storage conditions and re-test intervals.
What should appear on a melanotan II certificate of analysis?
A batch or lot number, declared sequence, manufacture and re-test dates, identity by MS (observed versus theoretical mass), HPLC purity with method conditions, related substances, net peptide content with water and counterion data, and appearance. Appended chromatograms and mass spectra let researchers verify the raw data independently.
References
- PMID:33245851 — LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs — Drug Test Anal — 2021
- DOI:10.1016/0024-3205(96)00160-9 — Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study — Life Sciences — 1996
- DOI:10.1002/jps.2600830805 — Preformulation Studies with Melanotan-II: A Potential Skin Cancer Chemopreventive Peptide — Journal of Pharmaceutical Sciences — 1994
- DOI:10.2174/0929866522666150622101944 — Analogue of Melanotan II (MTII): A Novel Melanotropin with Superpotent Action on Frog Skin — Protein & Peptide Letters — 2015
- DOI:10.2165/00128415-201214260-00111 — Melanotan II overdose — Reactions Weekly — 2012
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
